VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

Vaccine Detail

IBV Vaccine SZ200
Vaccine Information
  • Vaccine Name: IBV Vaccine SZ200
  • Target Pathogen: Infectious Bronchitis Virus (IBV)
  • Target Disease: Infectious Bronchitis
  • Type: Live, attenuated vaccine
  • Status: Research
  • Host Species for Licensed Use: None
  • Host Species as Laboratory Animal Model: chicken
  • Antigen: GI-19 genotype vaccine strain SZ (Zhao et al., 2019)
  • Preparation: The GI-19 genotype vaccine strain, SZ200, was attenuated in our laboratory with 200 serial passages in SPF embryonated chicken eggs via the allantoic sac route. (Zhao et al., 2019)
  • Immunization Route: intranasal immunization
  • Description: Live attenuated SZ200 vaccine protects chickens against IBV challenge. (Zhao et al., 2019)
Host Response

Chicken Response

  • Vaccination Protocol: Seventy-five 14-day-old SPF chickens were divided into six groups of 15 or 10 birds. Groups A (15 birds) and B (10 birds) were used as the negative controls. Groups C (15 birds) and D (10 birds) were vaccinated intranasally with 103.5 EID50 SZ200. Groups E (15 birds) and F (10 birds) were left unvaccinated. (Zhao et al., 2019)
  • Immune Response: c. The unvaccinated challenged group C showed a maximum average ciliostasis score of 4, whereas the average ciliostasis score in the SZ200-vaccinated group was <2. The difference in ciliostasis was extremely significant between the SZ200-vaccinated group and the unvaccinated group (p < 0.01). Significant reductions in the postchallenge viral load in the tissues of the SZ 200-vaccinated groups were detected at 3, 5, and 7 dpc compared with those in the unvaccinated group (p < 0.05). (Zhao et al., 2019)
  • Side Effects: In terms of the clinical manifestations, no gross lesions were observed in the SZ200-vaccinated group. (Zhao et al., 2019)
  • Challenge Protocol: All groups were challenged intranasally with LGD at a dose of 10^6.0 EID50/bird at 14 days postvaccination. (Zhao et al., 2019)
  • Efficacy: Compared with the unvaccinated challenged group (60% morbidity, 10% mortality), the SZ200 vaccine reduced the morbidity and mortality of the chickens infected with LGD. (Zhao et al., 2019)
References